Jonathan Allan Sells 2,266 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 2,266 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $19,646.22. Following the transaction, the general counsel now owns 33,510 shares in the company, valued at approximately $290,531.70. This trade represents a 6.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Stoke Therapeutics Stock Up 1.7 %

NASDAQ:STOK traded up $0.14 during trading hours on Monday, hitting $8.29. 964,264 shares of the company's stock traded hands, compared to its average volume of 840,350. Stoke Therapeutics, Inc. has a 52 week low of $6.29 and a 52 week high of $17.58. The business's fifty day simple moving average is $9.47 and its two-hundred day simple moving average is $11.39. The firm has a market cap of $448.31 million, a P/E ratio of -3.95 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics in the fourth quarter worth $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics during the fourth quarter worth about $113,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Stoke Therapeutics in the 4th quarter worth about $124,000. Tower Research Capital LLC TRC lifted its position in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after buying an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new stake in Stoke Therapeutics in the fourth quarter worth approximately $133,000.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and a consensus price target of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.